Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6991 to 7005 of 7690 results

  1. Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

    Discontinued [GID-TA10609]

    Technology appraisal guidance
    Discontinued

  2. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued [GID-TAG427]

    Technology appraisal guidance
    Discontinued

  3. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued [GID-TAG395]

    Technology appraisal guidance
    Discontinued

  4. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued [GID-TAG436]

    Technology appraisal guidance
    Discontinued

  5. Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

    Discontinued [GID-TA10390]

    Technology appraisal guidance
    Discontinued

  6. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued [GID-TA10202]

    Technology appraisal guidance
    Discontinued

  7. Galcanezumab for preventing cluster headache [ID1212]

    Discontinued [GID-TA10425]

    Technology appraisal guidance
    Discontinued

  8. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued [GID-TAG456]

    Technology appraisal guidance
    Discontinued

  9. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued [GID-TAG425]

    Technology appraisal guidance
    Discontinued

  10. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

    Discontinued [GID-TA10297]

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued [GID-TA10338]

    Technology appraisal guidance
    Discontinued

  12. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development [GID-HST10037] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  13. Lasmiditan for treating acute migraine [ID3759]

    Discontinued [GID-TA10807]

    Technology appraisal guidance
    Discontinued

  14. Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538]

    Discontinued [GID-TA10422]

    Technology appraisal guidance
    Discontinued

  15. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued [GID-TA10633]

    Technology appraisal guidance
    Discontinued